Related Experiment Video
Updated: Aug 16, 2026
12:03
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
Published on: June 7, 2016
Angiotensin II receptor antagonists: where do we stand?
1Division of Hypertension and Vascular Medicine, Avenue P Decker, CHUV, 1011 Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
Idrugs : the Investigational Drugs Journal
|August 17, 2005
Summary
Angiotensin II antagonists effectively manage hypertension with better tolerability than other agents. Ongoing trials assess their impact on major health outcomes and explore combination therapies.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Nephrology
Background:
- Losartan, the first angiotensin II receptor antagonist (ARB), launched in 1994.
- Five additional ARBs are now available for hypertension management.
- ARBs demonstrate comparable efficacy to other antihypertensives with improved tolerability.
Purpose of the Study:
- To evaluate the efficacy and tolerability of angiotensin II antagonists in managing hypertension.
- To investigate the potential benefits of ARBs on morbidity and mortality.
- To explore the role of angiotensin AT2 receptors and combination therapies.
Main Methods:
- Review of recent studies on ARBs.
- Analysis of ongoing large-scale clinical trials in hypertension, heart failure, and diabetic nephropathy.
- Focus on research defining the role of AT2 receptors and combined ACE inhibitor/ARB therapy.
Main Results:
- Angiotensin II antagonists are as effective as other antihypertensive agents.
- ARBs exhibit a superior tolerability profile.
- Large clinical trials are underway to establish benefits in morbidity and mortality.
Conclusions:
- Angiotensin II antagonists are a well-tolerated and effective class of antihypertensive drugs.
- Further research and large trials are crucial to confirm long-term benefits on major health outcomes.
- Investigating AT2 receptor roles and combination therapies holds promise for future cardiovascular and renal protection.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...